There are 9 resources available
Welcome and introduction
Presenter: G. Curigliano, IT, B. Pistilli, FR
Session: Opening and welcome
Resources:
Slides
Webcast
Integrating CDK4-6 inhibitors in patients with early HR positive / HER2 negative breast cancer: Successes and failures
Presenter: M. Gnant, AT
Session: Session 1 - CDK4-6 inhibitors in breast cancer
Resources:
Slides
Webcast
Ongoing clinical studies on CDK4-6 inhibition in early HR positive / HER2 negative breast cancer
Presenter: B. Pistilli, FR
Session: Session 1 - CDK4-6 inhibitors in breast cancer
Resources:
Slides
Webcast
Risk stratification in HR positive / HER2 negative early breast cancer: Lessons from neoadjuvant and adjuvant setting
Presenter: Ana Bosch, SE
Session: Session 1 - CDK4-6 inhibitors in breast cancer
Resources:
Slides
Webcast
CDK4-6 inhibition in patients with metastatic HR positive / HER2 negative breast cancer: Benefit in endocrine resistant disease
Presenter: A. Marra, IT
Session: Session 2 - CDK4-6 inhibitors in advanced breast cancer
Resources:
Slides
Webcast
Emerging data on new agents and new combinations in endocrine resistant disease
Presenter: G. Curigliano, IT
Session: Session 2 - CDK4-6 inhibitors in advanced breast cancer
Resources:
Slides
Webcast
Role of CD 4-6 inhibitors across enriched molecular subgroup
Presenter: A. Bosch, SE
Session: Session 3 - Research or rational combinations of CDK4-6 inhibitors with targeted agents
Resources:
Slides
Webcast
CDK4-6 inhibitors beyond CDK4-6 inhibitors in metastatic setting
Presenter: G. Curigliano, IT
Session: Session 3 - Research or rational combinations of CDK4-6 inhibitors with targeted agents
Resources:
Slides
Webcast
Clinical cases of high-risk patients with early HR positive / HER2 negative breast cancer candidate to adjuvant CDK4-6 inhibitors: Balancing efficacy and toxicity
Presenter: B. Pistilli, FR
Session: Session 1 Cont. - CDK4-6 inhibitors in breast cancer
Resources:
Slides
Webcast